ABOUT LEMAÎTRE

LeMaitre is a worldwide provider of medical devices and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. We develop, manufacture, and market implants and disposable devices, and process and cryopreserve allograft tissue. Our products and services are used primarily by vascular surgeons.

SALES & PROFIT GROWTH PLATFORM

Sales Force - Direct sales in 29 countries through 136 sales reps & 13 sales offices.
Acquisitions - 24 acquisitions completed in the last 26 years.
Factory Consolidations - 17 factory consolidations completed in the last 26 years.
R&D - 15 next-generation and new product launches completed in the last 23 years.

CASH RETURNS TO SHAREHOLDERS

LeMaitre will pay a quarterly dividend of $0.14 per share on 11/30/23.
LeMaitre authorized a $25mm share repurchase program on 2/21/23.

ANALYST COVERAGE

Barrington
Michael Petusky
mpetusky@brai.com
(312) 634-6320

Jefferies
Michael Sarcone
msarcone@jefferies.com
(212) 778-8606

JMP
David Turkaly
dturkaly@jmpsecurities.com
(212) 906-3563

Lake Street
Brooks O’Neill
brooks.oneill@lakестreetcm.com
(612) 249-8999

Oppenheimer
Suraj Kalia
suraj.kalia@opco.com
(212) 667-5387

ROTH
Scott Henry
shenry@roth.com
(949) 500-0863

Sidoti
James Sidoti
jsidoti@sidoti.com
(212) 453-7056

Stifel
Rick Wise
wiser@stifel.com
(212) 271-3806

CONTACT INFORMATION

George LeMaitre, Chairman & CEO
glemaître@lemaitre.com
(781) 425-1676

David Roberts, President
droberts@lemaitre.com
(781) 425-1693

JJ Pellegrino, CFO
jjpellegrino@lemaitre.com
(781) 425-1691
DISCLAIMERS
Unaudited Quarterly Financial Results
The quarterly financial results in this document are unaudited.

Forward-Looking Statements
This document contains certain forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Actual results and events may differ significantly from results and events described in forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those described in “Risk Factors” in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. We undertake no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date the statements were made.

Non-GAAP Financial Measures
This document contains non-GAAP financial measures. Non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles and may not be comparable to similar non-GAAP financial measures used by other companies. The most directly comparable financial measures calculated in accordance with GAAP and a reconciliation of GAAP to non-GAAP financial measures are provided at the end of this document.

Other
Unless otherwise specified, all information contained herein is provided as of September 30, 2023, except that all management guidance is as of November 1, 2023. This document is not a reaffirmation of management guidance.

<table>
<thead>
<tr>
<th>LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NON-GAAP FINANCIAL MEASURES (amounts in thousands) (unaudited)</td>
</tr>
</tbody>
</table>

### Reconciliation between GAAP and Non-GAAP sales growth:

For the three months ended September 30, 2023
- **Net sales as reported**: $47,411
- **Net distribution sales**: (1,341)
- **Impact of currency exchange rate fluctuations**: (728)
- **Adjusted net sales**: $45,342

For the three months ended September 30, 2022
- **Net sales as reported**: $39,028
- **Adjusted net sales**: $39,028

**Adjusted net sales increase for the three months ended September 30, 2023**: $6,314 (16%)

### Reconciliation between GAAP and Non-GAAP projected sales growth:

For the year ending December 31, 2023
- **Net sales per guidance (midpoint)**: $193,601
- **Net distribution sales**: (3,915)
- **Impact of currency exchange rate fluctuations**: 3
- **Adjusted projected net sales**: $189,689

For the year ended December 31, 2022
- **Net sales as reported**: $161,651
- **Adjusted net sales**: $161,651

**Adjusted projected net sales increase for the year ending December 31, 2023**: $28,038 (17%)

### Reconciliation between GAAP and Non-GAAP projected operating income:

For the year ending December 31, 2023
- **Operating income per guidance (midpoint)**: $36,506
- **Impact of special charge**: 485
- **Adjusted projected operating income**: $36,991

For the year ended December 31, 2022
- **Operating income as reported**: $26,829
- **Impact of special charge**: 3,107
- **Adjusted operating income**: $29,936

**Adjusted projected operating income increase for the year ending December 31, 2023**: $7,055 (24%)

### Reconciliation between GAAP and Non-GAAP projected EPS:

For the year ending December 31, 2023
- **EPS per guidance (midpoint)**: $1.33
- **Impact of special charge, including tax**: 0.01
- **Adjusted EPS**: $1.34

For the year ended December 31, 2022
- **EPS as reported**: $0.93
- **Impact of special charge, including tax**: 0.13
- **Adjusted EPS**: $1.06

**Adjusted projected EPS increase for the year ending December 31, 2023**: $0.28 (26%)